Zobrazeno 1 - 10
of 98
pro vyhledávání: '"David Ungar"'
Autor:
Juan P. Alderuccio, Weiyun Z. Ai, John Radford, Melhem Solh, Kirit M. Ardeshna, Matthew A. Lunning, Brian T. Hess, Pier L. Zinzani, Anastasios Stathis, Carmelo Carlo-Stella, Mehdi Hamadani, Brad S. Kahl, David Ungar, Turk Kilavuz, Eric Yu, Yajuan Qin, Paolo F. Caimi
Publikováno v:
Alderuccio, J P, Ai, W Z, Radford, J, Solh, M M, Ardeshna, K M, Lunning, M, Hess, B, Luigi Zinzani, P, Stathis, A, Carlo Stella, C, Hamadani, M, Kahl, B S, Ungar, D, Kilavuz, T, Yu, E, Qin, Y G & Caimi, P F 2022, ' Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma : a subgroup analysis from the LOTIS-2 study ', Blood Advances, vol. 6, no. 16, pp. 4736-4739 . https://doi.org/10.1182/bloodadvances.2022007782
Autor:
Owen A. O'Connor, Karin Havenith, Joseph Boni, Shui He, David Ungar, Leonard T. Heffner, Melhem Solh, Kirit M. Ardeshna, Jay M. Feingold, Erin Reid, Paolo Caimi, Carmelo Carlo-Stella, John Radford, Mehdi Hamadani, Brad S. Kahl
Supplementary Figure 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d358307749caa66ce36654aebc7606c
https://doi.org/10.1158/1078-0432.22472163.v1
https://doi.org/10.1158/1078-0432.22472163.v1
Autor:
Owen A. O'Connor, Karin Havenith, Joseph Boni, Shui He, David Ungar, Leonard T. Heffner, Melhem Solh, Kirit M. Ardeshna, Jay M. Feingold, Erin Reid, Paolo Caimi, Carmelo Carlo-Stella, John Radford, Mehdi Hamadani, Brad S. Kahl
Supplementary Figure 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07fe7f74a6d29154a68f46d0c4dec53c
https://doi.org/10.1158/1078-0432.22472166
https://doi.org/10.1158/1078-0432.22472166
Autor:
Owen A. O'Connor, Karin Havenith, Joseph Boni, Shui He, David Ungar, Leonard T. Heffner, Melhem Solh, Kirit M. Ardeshna, Jay M. Feingold, Erin Reid, Paolo Caimi, Carmelo Carlo-Stella, John Radford, Mehdi Hamadani, Brad S. Kahl
Supplementary Materials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1018abd11fdea321417b9a9ed850f8a5
https://doi.org/10.1158/1078-0432.22472160.v1
https://doi.org/10.1158/1078-0432.22472160.v1
Autor:
Owen A. O'Connor, Karin Havenith, Joseph Boni, Shui He, David Ungar, Leonard T. Heffner, Melhem Solh, Kirit M. Ardeshna, Jay M. Feingold, Erin Reid, Paolo Caimi, Carmelo Carlo-Stella, John Radford, Mehdi Hamadani, Brad S. Kahl
Purpose:ADCT-402 (loncastuximab tesirine) is an antibody–drug conjugate comprising a CD19-targeting antibody and pyrrolobenzodiazepine dimers. A first-in-human study evaluated the safety and preliminary clinical activity of loncastuximab tesirine i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e4059cd5b5e1a0230f5014369dfa698
https://doi.org/10.1158/1078-0432.c.6528141
https://doi.org/10.1158/1078-0432.c.6528141
Autor:
Alexander Spira, Laura Liao, Xiaolei Zhou, Bintu Sherif, Lei Chen, David Ungar, Eric Yu, John Radford, Mehdi Hamadani
Publikováno v:
Journal of the National Comprehensive Cancer Network. 20:HSR22-171
Autor:
Laura Liao, Brad S. Kahl, John Radford, Xiaolei Zhou, David Ungar, Ari Gnanasakthy, Rafael E. Curiel, Luqiang Wang, Lei Chen, Alexander I. Spira
Publikováno v:
Spira, A, Zhou, X, Chen, L, Gnanasakthy, A, Wang, L, Ungar, D, Curiel, R, Liao, L, Radford, J & Kahl, B 2021, ' Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma ', Clinical Lymphoma, Myeloma and Leukemia . https://doi.org/10.1016/j.clml.2021.09.001
Background Loncastuximab tesirine has shown antitumor activity with an acceptable toxicity profile in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who were relapsed or refractory after ≥2 prior therapies, including act
Autor:
Melhem Solh, Karin Havenith, Jay Feingold, Brad S. Kahl, Erin Reid, Luqiang Wang, Carmelo Carlo-Stella, Leonard T. Heffner, John Radford, Owen A. O'Connor, Paolo Caimi, William Townsend, Joseph Boni, Kirit M. Ardeshna, David Ungar, Yajuan Gu Qin, Mehdi Hamadani
Publikováno v:
Blood
Hamadani, M, Radford, J, Carlo-Stella, C, Caimi, P F, Reid, E G, O'Connor, O A, Feingold, J, Ardeshna, K M, Townsend, W M, Solh, M, Heffner, L T, Ungar, D, Wang, L, Boni, J P, Havenith, K, Qin, Y G & Kahl, B 2021, ' Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma ', Blood, vol. 137, no. 19, pp. 2634-2645 . https://doi.org/10.1182/blood.2020007512
Hamadani, M, Radford, J, Carlo-Stella, C, Caimi, P F, Reid, E G, O'Connor, O A, Feingold, J, Ardeshna, K M, Townsend, W M, Solh, M, Heffner, L T, Ungar, D, Wang, L, Boni, J P, Havenith, K, Qin, Y G & Kahl, B 2021, ' Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma ', Blood, vol. 137, no. 19, pp. 2634-2645 . https://doi.org/10.1182/blood.2020007512
The prognosis for patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) remains poor, with a need for alternatives to current salvage therapies. Loncastuximab tesirine (ADCT-402) is an antibody-drug conjugate comprising a hum
Autor:
Bhavana Bhatnagar, Ehab Atallah, Benjamin Tomlinson, Leonard T. Heffner, James K. McCloskey, Yajuan Qin, Karin Havenith, Hagop M. Kantarjian, Xiaoyan Zhang, Wendy Stock, Matthew J. Wieduwilt, Nitin Jain, Jay Feingold, Grace Chao, David Ungar, Amer M. Zeidan
Publikováno v:
Blood Advances. 4:449-457
Relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) remains a therapeutic challenge. Loncastuximab tesirine is an antibody-drug conjugate against CD19, an antigen expressed in many B-cell malignancies. This open-label, single-arm
Autor:
Brian T. Hess, Pier Luigi Zinzani, Kirit M. Ardeshna, John Radford, Mehdi Hamadani, Brad S. Kahl, Anastasios Stathis, David Ungar, Yajuan Qin, Weiyun Z. Ai, Shui He, Melhem Solh, Paolo Caimi, Juan Pablo Alderuccio, Jay Feingold, Carmelo Carlo-Stella
Publikováno v:
Blood. 136:35-37
Introduction: Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who fail multi-agent chemoimmunotherapy have a poor prognosis and a need for more treatment options. Loncastuximab tesirine (Lonca) comprises a humanized a